XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Doublecortin-like kinase 1 (DCLK1) is a key cancer stem cell marker highly expressed in various human cancers.
• DCLK1 is a protein kinase targeted for cancer therapy, but clinical drug candidates are lacking.
• Targeting DCLK1 offers a promising strategy for novel cancer therapeutics.

Purpose of the Study:

• To investigate the DCLK1 kinase inhibitory activity of XMD-17-51.
• To evaluate the effects of XMD-17-51 on non-small cell lung carcinoma (NSCLC) cell proliferation, epithelial-mesenchymal transition (EMT), and stemness.
• To assess the therapeutic potential of XMD-17-51 for lung cancer.

Main Methods:

• Cell-free enzymatic assay to determine DCLK1 kinase inhibitory activity (IC50).
• Assessment of XMD-17-51's impact on NSCLC cell proliferation and DCLK1 overexpression effects.
• Analysis of protein levels related to EMT (Snail-1, ZEB1, E-cadherin) and stemness markers (β-catenin, SOX2, NANOG, OCT4).
• Sphere formation and ALDH+ cell assays to evaluate cancer stem cell properties.

Main Results:

• XMD-17-51 demonstrated potent DCLK1 kinase inhibition with an IC50 of 14.64 nM.
• XMD-17-51 inhibited NSCLC cell proliferation and decreased DCLK1 protein levels.
• The compound reduced EMT by decreasing Snail-1 and ZEB1, and increasing E-cadherin.
• XMD-17-51 suppressed sphere formation and key stemness markers, although ALDH+ cell percentage increased.
• DCLK1 overexpression partially rescued the anti-proliferative effect of XMD-17-51.

Conclusions:

• XMD-17-51 effectively inhibits DCLK1 kinase activity and reduces cancer stem cell characteristics in NSCLC.
• The compound's ability to inhibit EMT and stemness suggests a dual mechanism of action.
• XMD-17-51 represents a promising drug candidate for the development of novel lung cancer therapies.